Journal
EUROPEAN UROLOGY
Volume 67, Issue 6, Pages 1099-1109Publisher
ELSEVIER
DOI: 10.1016/j.eururo.2014.12.038
Keywords
Clinical practice guidelines; Diagnosis; Lower urinary tract symptoms; Bladder outlet obstruction; Benign prostatic hyperplasia; Detrusor overactivity; Overactive bladder; Nocturia; Nocturnal polyuria
Categories
Funding
- Pierre Fabre Medicament
- GSK
- Angelini Pharma Hellas
- Astellas
- MSD
- Bayer Healthcare
- AMS
- Recordati
- DFG
- EUSP
- AstraZeneca
- Pfizer
- Ferring
- Apogepha
- Allergan
- Porge-Coloplast
- Ariti
- Karl Storz Endoscope
- Cook Medical
- Boston Scientific
- Eli-Lilly
- Mundipharma
- Teva
Ask authors/readers for more resources
Context: Lower urinary tract symptoms (LUTS) represent one of the most common clinical complaints in adult men and have multifactorial aetiology. Objective: To develop European Association of Urology (EAU) guidelines on the assessment of men with non-neurogenic LUTS. Evidence acquisition: A structured literature search on the assessment of non-neurogenic male LUTS was conducted. Articles with the highest available level of evidence were selected. The Delphi technique consensus approach was used to develop the recommendations. Evidence synthesis: As a routine part of the initial assessment of male LUTS, a medical history must be taken, a validated symptom score questionnaire with quality-of-life question(s) should be completed, a physical examination including digital rectal examination should be performed, urinalysis must be ordered, post-void residual urine (PVR) should be measured, and uroflowmetry may be performed. Micturition frequency-volume charts or bladder diaries should be used to assess male LUTS with a prominent storage component or nocturia. Prostate-specific antigen (PSA) should be measured only if a diagnosis of prostate cancer will change the management or if PSA can assist in decision-making for patients at risk of symptom progression and complications. Renal function must be assessed if renal impairment is suspected from the history and clinical examination, if the patient has hydronephrosis, or when considering surgical treatment for male LUTS. Uroflowmetry should be performed before any treatment. Imaging of the upper urinary tract in men with LUTS should be performed in patients with large PVR, haematuria, or a history of urolithiasis. Imaging of the prostate should be performed if this assists in choosing the appropriate drug and when considering surgical treatment. Urethrocystoscopy should only be performed in men with LUTS to exclude suspected bladder or urethral pathology and/or before minimally invasive/surgical therapies if the findings may change treatment. Pressure-flow studies should be performed only in individual patients for specific indications before surgery or when evaluation of the pathophysiology underlying LUTS is warranted. Conclusions: These guidelines provide evidence-based practical guidance for assessment of non-neurogenic male LUTS. An extended version is available online (www.uroweb.org/guidelines). Patient summary: This article presents a short version of European Association of Urology guidelines for non-neurogenic male lower urinary tract symptoms (LUTS). The recommended tests should be able to distinguish between uncomplicated male LUTS and possible differential diagnoses and to evaluate baseline parameters for treatment. The guidelines also define the clinical profile of patients to provide the best evidence-based care. An algorithm was developed to guide physicians in using appropriate diagnostic tests. (C) 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available